LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 06/16/23

Blood glucose levels reduced by 19.9% with DehydraTECH-CBD Improvements in kidney function also demonstrated KELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pl...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held seni...

(TheNewswire) Kelowna, British Columbia – TheNewswire - June 12, 2023 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces the appointment of a new ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The findings demonstrate significant reductions in several pro-inflammatory biomarkers known to be linked to card...

(TheNewswire) DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility Kelowna, BC - TheNewswire - May 23, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”) , a ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in ...

900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH KELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its animal study HOR-A22-1 has...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, has announced the closing of its public offering of 2,106,000 units, with each consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold at a public of...

(TheNewswire) Kelowna, British Columbia – TheNewswire - May 11, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its public offering of 2,106,000 units,...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced completion of batch manufacturing of the DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for its upcoming U.S. phase 1b hypertension clinical trial HYPER-H23...